Project Details
Description
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C previously treated with an NS5A Inhibitor + Sofosbuvir Therapy? (Protocol number B16-439; or DAA-SALVAGE
| Status | Finished |
|---|---|
| Effective start/end date | 3/20/17 → 12/31/18 |
Funding
- UNIVERSITY OF FLORIDA
- ABBVIE INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.